Can topical applied patches adhere without causing irritation in Vulvar Lichen Sclerosus patients?

Ditte Marie L. Saunte1,2, Martin Gormsen3, Lars S. Madsen3, Gregor B.E. Jemec1,2
1Department of Dermatology, Zealand University Hospital, Roskilde
2Health Sciences Faculty, University of Copenhagen, Denmark
3AFXY Therapeutics, formerly known as Dermitreat, 2300 Copenhagen S, Denmark

Introduction
Vulvar lichen sclerosus (VLS) is a chronic inflammatory skin disease with a predilection for the anogenital area. It is estimated that up to 3% (1:30) of perimenopausal/menopausal women have vulvar lichen sclerosus. The symptoms are dyspareunia, dysuria, perianal discomfort, pruritus and pain. Typical clinical signs is thickening of the skin, dyspigmentation, fissuring, ecchymoses, hyperkeratosis and inflammation. Topical corticosteroids is the gold stand of therapy and long-term treatment can reduce the disease-associated risk of spinoctellar carcinoma, which occurs in up to 6% of woman with Vulvar Lichen Sclerosus1,2,3.

It presents clinically as areas of atrophy, edema, fissures, erosion and/or thickened hyperkeratotic plaques.4 The initial treatment regimen consists of daily application of topical corticosteroids. Irritation from changes in microbiome and mechanical shear are thought to influence the disease severity.5

An adhesive patch has been developed to form a protective barrier over VLS lesions thereby potentially also contribute to pain relief.

The present study was conducted in order to explore the adherence and tolerability of plain patches (without medication) when applied directly to VLS lesions.

Objectives
The present study was conducted in order to explore the adherence and tolerability of plain patches (without medication) when applied directly to VLS lesions.

Materials & Methods
This was an open-label study. Eligible subjects were women (≥ 18 years) diagnosed with VLS which had signed an informed content. Pregnant or menstruating patients at the time of patch application were excluded. The primary endpoint was applications of the patches and adhesion for ≥ 30 min. Secondary endpoints were frequency and intensity of adverse events collected during the investigation, subject’s ability to apply patches correctly and understanding of the ‘instructions for use’ leaflet.

A visual analogue scale (VAS) for discomfort, pain, itching and burning was used at baseline, at 2 h after application (or when the patch detached) and on day 2 (VAS 0–10, where 0 = no symptom and 10 = worst possible). At the same time physical examination grading redness, erosion and edema was performed (graded from 0 (no signs) to 4 (maximum)). Ten questions regarding the comfort, adhesion and the willingness to wear the patch containing medications was fulfilled day 2.

Activity

<table>
<thead>
<tr>
<th>Activity</th>
<th>Timing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Activity Day 1</td>
<td></td>
</tr>
<tr>
<td>Potent application and written informed consent</td>
<td>1 h</td>
</tr>
<tr>
<td>Assessment and Treatment</td>
<td>3 h</td>
</tr>
<tr>
<td>Instructions on applying patches and application of patches</td>
<td>1 h</td>
</tr>
<tr>
<td>Removal of patch (if not detached)</td>
<td>2 h</td>
</tr>
<tr>
<td>Assessment of mucosal irritation and subject VAS</td>
<td>2 h</td>
</tr>
<tr>
<td>Activity Day 2</td>
<td></td>
</tr>
<tr>
<td>Assessment of mucosal irritation and subject VAS</td>
<td>2 h</td>
</tr>
</tbody>
</table>

Results (continued)

Baseline VLS symptoms by VAS scoring was as follows: pain (mean 2.6, range 0-7), itch (mean 3.8, range 0-10), burning (mean 3.3, range 0-8) and discomfort (mean 4.1, range 0-8) (Fig. 2). All patients were able to apply the plain patch. The mean adhesion time was 9.5 h on Day 1 and 10.0 h on Day 2. No AEs were reported. All subjects applied the patches correctly and were able to follow the leaflet instructions.

The measured VLS symptoms VAS scores (discomfort, pain, itching and burning) were lower 2 hours after application and on day 2 compared to baseline. In addition, for both redness, erosion and oedema, all subjects (except for 1) had scores of 0 or 1 on both day 1 and 2. For the physical examination of the mucosa and skin (vulva and anal area) 5 subjects (41.7%) had a shift from abnormal to normal for either skin or mucosa or both while no change were reported for the rest (58.3%) of the subjects. The overall response to the design of the patches was that they were easy and quick to apply.

Discussion

The primary objective to investigate the adhesion time of the plain patches to VLS lesions was met as all subjects reported a successful application with a mean adhesion time for both morning and evening of more than 9 hours. For all symptoms of VLS the VAS scores were lower after patch application compared to prior to application indicating a reduction in the subjects’ evaluation of the level of VLS symptoms after using the patch. No safety issues were reported and the patch were well tolerated when applied to sensitive VLS lesions.

Acknowledgement
MG and LSM received a grant from the Innovation Fund, Denmark.

References